Miso Clinic · Clinical columns
Clinical columns — the questions that actually come up
Where the reference library answers “what is this product”, this is where we answer “what does that mean for me”. Written for the person who does not yet know which question to ask, rather than the one who already knows the product name. All written and reviewed by Dr. Lee Chi-Hak, in Korean and English. To start from a concern without knowing product names, see the treatment guides; for the difference between two products, the comparisons.
Why this is separate from the reference library
Product references have an end. Seven boosters and three lifting devices — once those ten are written, there is not much left to add.
But the questions people actually ask in the consulting room do not start with a product name. They are “the bruise is still there after two weeks, is that normal” and “what am I supposed to tell you beforehand”. Those questions are endless, and answers are hard to find — largely because no advertisement can be attached to them, so nobody writes them.
So this column starts from the situation, not the product. Different in kind, so kept separate.
Columns
| Density vs XERF in Daegu: which is better? Results, differences and who each suits | September 2026 · No study has compared the two devices in people. The design difference (polarity versus frequency), the published results and pain scores, and which face each is considered first for, side by side. |
|---|---|
| Sagging or loss of firmness: is Density or XERF the better fit? | September 2026 · Sorting sagging from thinning skin and volume loss first, then when Density or XERF is a candidate, when neither is, and which to consider first, in one table. |
| Choosing between Density and XERF in Daegu: what to check and how to decide | September 2026 · No public metric identifies the clinic that does it best. Five things to check when weighing both devices, and criteria built on tips, shots, sessions, who scored the results and accurate approval wording. |
| GOURI in Daegu: seven things to check before you choose a clinic | September 2026 · No public metric compares injector skill. Seven items — structural assessment, dose per area, irreversibility, session basis, aftercare — each take one question to settle. |
| GOURI in Daegu: which skin types is it actually for | September 2026 · Which skin states make GOURI a candidate and which rule it out, and how far “better for thin skin” has been measured rather than inferred. |
| GOURI vs Rejuran vs Rituo vs Juvelook vs Sculptra — choosing a collagen treatment | September 2026 · Five products on three criteria: depth of human data, reversibility, and where the session count comes from. No head-to-head trial exists among them. |
| Lumpiness after GOURI — why it happens and how to avoid it | September 2026 · Whether a lump appeared within two weeks decides what it is. Four routes, nodule rates with denominators, and which preventives are supported. |
| What It Means to Dilute CaHA — Not Making It Weaker, Making It Reach Further | September 2026 · Fibroblasts responded only where they touched a particle, and output per cell was the same at every dilution. No human data show 1:4 beating 1:2. |
| Ulthera (Ultherapy) — a device we do not have, and its evidence is thicker than ours | September 2026 · A device we do not have. In the one trial with an untreated control arm, blinded judgement at 90 days was 54.2% versus 47.0%; investigators rated 96.8%. |
| Retaining ligament filler — how far does the evidence actually go | September 2026 · The most-cited report is a 45-patient case series, and the ligament anatomy itself is still disputed. Including data showing midface filler stays longer than assumed. |
| Looking into XERF in Daegu — filling in the material we had missed | September 2026 · Two more studies in humans appeared in 2026, and one paper we cited had its conflict of interest statement corrected. What is confirmed and what is not. |
| Nasolabial Folds in Daegu — Is What Is Measured a Wrinkle, or a Shadow? | September 2026 · What the nasolabial fold scale actually measures is depression and shadow. We set out the data in which grade and grey value correlated at 0.985. |
| Cheek Sagging in Daegu — Is There a Treatment That Deals With the Cheek Alone? | September 2026 · The jawline, the chin and the nasolabial fold have validated scales; for the cheek we could not find one. We set this out from the primary sources. |
| Facial Sagging in Daegu — Starting With Which Layer the Treatment Works On | September 2026 · What the primary endpoint of the sagging trials actually was, and how much layer thickness differs from person to person, taken from the primary sources. |
| Comparing Types of Skin Booster in Daegu — What Is Verified Class by Class, and What Is Not | September 2026 · Each class measured something different, with different sample sizes. We set seven in the same columns and separate what is verified from what is not. |
| Collagen Boosters in Daegu — Where “It Increases Collagen” Was Measured in People | September 2026 · How many people the human tissue data behind it increases collagen covers, and what those studies actually measured, set out from the primary sources. |
| Fine Lines and Skin Texture in Daegu — May They Be Grouped Into One Treatment? | September 2026 · In the literature, fine lines and skin texture are graded on separate scales. We set out the primary data showing that rater reliability differs by area. |
| Choosing a Skin Firmness Treatment in Daegu — What Is “Firmness” Measured With? | September 2026 · On the measuring device, firmness is a value with three names. We set out the primary data showing that the result turns on which one was measured and how. |
| A Natural Lifting in Daegu — What Is Actually Being Adjusted | September 2026 · Scales that measure naturalness are validated, but we could not find one registered lifting trial using it as an outcome. Consensus gives no upper bound. |
| Skin Boosters in Daegu — What Has to Be Settled Before the Product Name | September 2026 · The MFDS itself writes skin booster as a so-called term. The one paper that tried to define it was retracted, and head-to-head trials are few. |
| What We Check When You Are Looking Into Re2O (hADM) in Daegu | September 2026 · Re2O is classified as human tissue, so no product-level approval number exists in the system. The published human trial is one: 20 people, 20 weeks. |
| Loss of firmness — “sagging” and “firmness” are not the same word | September 2026 · In 112 Korean women, sagging explained 37% of how old a face reads. The only factor that predicted response was tissue mobility, not age or skin thickness. |
| Pores — what treatment can and cannot reduce | September 2026 · Data evaluating pores as a primary endpoint is thin across every class. We separate what the data supports from what is only a mechanistic explanation. |
| Skin texture — what explains about 80% of perceived facial age | September 2026 · Skin texture explained about 80% of the variance in perceived facial age. Shown only cheek skin, estimated ages ranged from 17.3 to 53.1 years. |
| Fine lines — first separate expression from dermis | September 2026 · Fine lines split into those made by expression and those settled in as the dermis thins. The two have different answers, and mixing them misdirects care. |
| Cheek sagging — we start by asking what has descended | September 2026 · Cheek sagging is usually not stretched skin but descended fat compartments. In cadaver measurements, superficial fat varied about 3.2-fold by region. |
| Nasolabial folds — the answer starts by separating the cause | September 2026 · A nasolabial fold is not folded skin. It is a structural boundary where facial muscle attaches to dermis, and three causes split the answer three ways. |
| Focused Ultrasound (HIFU) and Radiofrequency (RF) — They Are Not Competing Technologies | September 2026 · Radiofrequency heats a broad volume; focused ultrasound places coagulation points at a set depth. Different layers, so the question has no answer. |
| Density and Oligio — Before Comparing, You Have to Settle Which Oligio | September 2026 · The name Oligio refers to three different products. No study comparing either directly with Density has been identified. Neither has a control group. |
| Density and XERF — Both “Use Two Things,” but They Combine Along Different Axes | September 2026 · Density combines two polarities; XERF combines two frequencies. No study comparing the two devices directly in humans has been identified. No controls. |
| Rituo and Rejuran — What Divided Them Was the Regulatory Pathway, Not the Material | September 2026 · The biggest difference is not the material but whether there was a legal duty to submit human clinical data before the product reached the market. |
| GOURI and Rejuran — What Differs, and What Has Not Yet Been Compared | September 2026 · No study has compared the two directly in humans. What separates them most is not the material but the gate each passed to reach approval. No controls. |
| If You Are Having a GOURI Consultation in Daegu — What Miso Clinic Actually Looks At | September 2026 · "Who does it best" cannot be answered from public data. What can be judged is what a clinic asks you at the consultation, and what it says it will not do. |
| How Many GOURI Sessions, How Far Apart — Three Numbers That Disagree | September 2026 · The manufacturer default is one session. For the "three sessions" figure in circulation we could not find a primary source, and no trial compares by count. |
| GOURI and the Other Skin Boosters — What Separates It from Rejuran, Juvelook and Radiesse | September 2026 · What separates these products is not the material but how thick the data behind each one is. GOURI sits on the thin side of that comparison. |
| Which Skin Is GOURI Suited To — the Director of Miso Clinic Explains | September 2026 · No study has broken the data down by skin type. What actually divides the decision is whether the problem is lost volume or skin that has thinned. |
| How GOURI Is Said to Build Collagen — the Mechanism, and How Far It Has Been Confirmed | September 2026 · The mechanism is described in the manufacturer's patent and was confirmed in rats at six weeks. In human tissue we could not find a single study. |
| GOURI away from the face — neck, eyes, hands | September 2026 · The manufacturer's own FAQ says face only, and that hand and neck data is still being collected. Every published human study covers the face. |
| Before a GOURI injection — what this product changes | September 2026 · The first thing is that it cannot be reversed. No contraindication data exists for liquid PCL, and the lists in circulation come from distributor pages. |
| GOURI and Sculptra — what actually differs | September 2026 · Both stimulate collagen, but material, plane and evidence differ. Liquid PCL has 33 people and 6 months; Sculptra, a 233-person trial and 25 months. |
| How far RADIESSE (CaHA) has been confirmed as a material | September 2026 · In March 2026 the US FDA approved RADIESSE diluted 1:2 for the decolletage, and in a trial of 152 people the 24-week improvement split 71.2% against 6.3%. |
| Why OLIGIO KISS puts two things into one device | September 2026 · In 20 women over 24 weeks, OLIGIO significantly improved jawline sagging at 12 weeks and cheek firmness from week 4, with no burns. KISS adds ultrasound. |
| How many shots — what the number ‘shots’ really is | September 2026 · A shot is not a dose the operator sets but a count sealed into the tip. No human study compares 300 with 600, and the maker ends on heat feedback. |
| The four EFFECTOR tips — what changes when the tip changes | September 2026 · A small tip heats harder, a large one heats deeper. But nobody has measured depth by tip size in human skin, and the one comparison found no difference. |
| How far the evidence for XERF has come | September 2026 · Three human studies of XERF exist (20, 39 and 16 people). None has a control group, and the 510(k) summary says no clinical tests were submitted. |
| Monopolar and bipolar — what is different | September 2026 · What sets the depth is the electrode, not the polarity. With tissue dielectric data, the lower-frequency-goes-deeper rule decides nothing at skin scale. |
| GOURI — from the day of the injection to months later | September 2026 · Set out in order from the day of injection to months later. All the published human data on liquid PCL is 33 people, and the longest follow-up is 6 months. |
| CellREDM · Re2O and Rejuran — what is different | September 2026 · One is human tissue, the other a medical device. The US holds that dermis ground into particles is no longer tissue. No study has compared them directly. |
| BYRYZN — filler or booster | September 2026 · By approval it is a filler. The only paper on this product is titled filler as a skin booster, and the FDA label for the same class records lumps at 63.3%. |
| Domestic and export-only — the same-looking approval number, a different standing | September 2026 · Export-only devices get genuine MFDS approval numbers but cannot be used on patients in Korea. 745 of 1,010 tissue-filling items were export-only. |
| The collagen boosters are said to make — type I and type III, and how it is measured | September 2026 · The stain believed to distinguish collagen types does not. What is confirmed in human tissue for each class, and where the method changes the answer. |
| Adverse events by booster class — what is common, and when it appears | September 2026 · In one trial bruising was 63.2% in patient diaries and 0.0% in physician records. The rates confirmed for each product class, and how to read them. |
| Hyaluronidase — what it can reverse and what it cannot | September 2026 · Hyaluronidase breaks down hyaluronic acid only. Korean labels carry no filler-dissolution indication, resistance differs 12.5-fold, CaHA has no antidote. |
| When Botox starts to work and how long it lasts — the numbers verified area by area | September 2026 · Onset, duration, dose by area and adverse events, written down exactly as the prescribing information and the randomised controlled trials give them. |
| It is the same polycaprolactone, so what is different between the liquid form and the microsphere-based form | September 2026 · We have put the composition, degradation, approval and safety side by side and written down what is verified and what is not yet. |
| Why the area under the eyes looks hollow, and how we approach the indian jureum (the Korean term for the tear-trough groove) | September 2026 · We have set out in figures what the structure is, what has been verified, and what has to be watched for in this area. |
| Nodules that form after a procedure — how common, when they appear, and what we do | September 2026 · The incidence is under 1% in most of the data. We have set out when they appear, what separates one kind from another, and what we do, together with the figures. |
| Jeheo · suheo · certification — what one line of approval number can and cannot tell you | September 2026 · How to read the number, how to look it up yourself, and the scope that number guarantees, set out together with the provisions. |
| What is different about the hyaluronic acid used in skin boosters | September 2026 · We have set out, as they stand, what cross-linked and non-cross-linked exactly are, the measured values for commercial products, and the results of the placebo-controlled trial. |
| The things called ‘collagen boosters’ — what has been verified, class by class | September 2026 · We have separated the six classes by ingredient and set out, as they stand, the figures verified in people and their sources. |
| How far exosome preparations have actually been verified | September 2026 · The international society does not recommend the term. In Korea these are cosmetics for topical use, and even the best clinical trial tested topical application. |
| Anti-ageing treatments for thin, dry skin | September 2026 · There is barely any study stratifying by thin skin. What is established lies on the safety side, not the efficacy side. |
| Why skin becomes more sensitive after laser treatment, and how to care for it | September 2026 · The barrier breaks down within a day and recovers in a week to a month depending on the site. Much of the standard aftercare is convention without evidence. |
| What changes when the skin barrier breaks down | September 2026 · Even stripped away completely, the stratum corneum recovers in 72 hours. But when recovery starts differed with age. |
| Why nasolabial folds deepen, and what actually improves them | September 2026 · A nasolabial fold is not something new appearing; it is a boundary that was always there coming to look deeper. Only what we verified. |
| Why you still look your age after the wrinkles are gone | September 2026 · In Korean data the weights for perceived age were wrinkles 37%, sagging 37%, pigmentation 26%. Wrinkles and sagging are level. |
| Five things to check before a lifting treatment | September 2026 · An approval number and an advertising review number are two different numbers. Here are five things you can verify at any clinic. |
| How lifting treatment differs for men | September 2026 · Across more than 60 RF and ultrasound studies, not one reports results broken down by sex. The only firmly evidenced sex difference is botulinum toxin dosing — and the “male skin is 20–25% thicker” figure comes from the forearm, not the face. |
| Filler or skin booster: what actually differs? | September 2026 · They do not separate by material or by regulation, and the one paper that tried to define “skin booster” was retracted. The three things that do separate them — and the one that matters most: can it be reversed? |
| When results actually appear, and when to judge them | September 2026 · In Korean patients there was no significant improvement at 4 weeks; it became significant at 12. At day 90 clinicians saw 92% improved and patients saw 42% — and at one year it flips. |
| Aftercare after radiofrequency treatment | September 2026 · Most of the standard advice turned out to be carried over from laser and microneedle protocols with no supporting study. Two things do matter: burns show within 72 hours, contour depressions at 1–4 months. |
| Density, XERF and Oligio: all radiofrequency, so what differs? | September 2026 · Current path, frequency and target layer differ. Only the specifications we could confirm on the manufacturers’ own pages — and the fact that no randomised trial has ever compared these devices head to head. |
| What actually separates a natural-looking face from an overdone one? | September 2026 · Attractiveness was predicted by averageness, not symmetry, and roughly 80% of perceived age was explained by skin texture, not shape. Including why the “facial golden ratio” cannot be used as evidence. |
| The 30s, 40s and 50s: what actually changes in lifting treatment | September 2026 · Korean women reach natural menopause at about 49–50. Why the 30s are almost absent from the evidence — and the study in which age was not what predicted response. |
| Lifting treatment should be adjusted to skin thickness and fat volume | September 2026 · In cadaver measurements, superficial facial fat varied more than threefold between regions. How fixed-depth cartridges and electrode size meet that variation, how far the evidence for individualisation actually goes — and the study that points the other way. |
| hADM (Re2O · CellREDM): how far has it actually been established? | September 2026 · The only booster family that supplies the material itself. What mouse histology actually showed, how far the human studies go, and the rule amendment the MFDS put out for comment in August 2026. |
| Juvelook (PDLLA): how far has it actually been established? | August 2026 · PDLLA microspheres plus hyaluronic acid. How far the published human data reach, and what has not been confirmed. |
| "Should I have a booster, or a lifting treatment?" | August 2026 · Why "boosters or lifting" is a sorting question, not a choice. What each treats, how to tell which one your concern is, and the fact that "combining works better" was directly tested twice and found no difference. |
| "Is a needle better, or a cannula?" | August 2026 · Why we inject Rejuran with a needle. What the cadaver studies show about where each tool puts the drug, how small the pain difference really is, and the fact that no needle-versus-cannula study exists for PN at all. |
| "How many sessions, and how long does it last?" | August 2026 · The answer differs by family — and so does how thick the evidence behind that answer is. Both are set out here. |
| "But a lot of the reviews say it did nothing" | August 2026 · Opposite reviews of the same product are usually not the fault of the product. Here is what they are usually about. |
| "The bruise is still there after two weeks" | August 2026 · Most of the time you simply wait. But there are cases where waiting is the wrong thing to do, and they look different. |
| “Is it approved?” | August 2026 · What the long numbers actually mean — licence versus advertising review, products not subject to licensing, and where all ten of ours actually stand. |
| Eight things to tell your doctor before an injectable treatment | August 2026 · Medications, previous injectables, a recent infection or an upcoming dental appointment — why we ask, and what changes when you leave something out. |
How these are written
- They have an author. Every column is written and reviewed by Dr. Lee Chi-Hak, and names the clinic at the foot of the page
- Figures are sourced. Where a number appears, so does the study it came from and the limits of that study. Figures we cannot verify are not published
- No prices, no promotions. This is not marketing material
- Including what does not favour us. Sometimes the right answer is to do nothing, or to go elsewhere
- Not a substitute for consultation. The same symptom can have different causes and therefore different answers
Who writes this
These columns are written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu, South Korea. The clinic keeps seven collagen and skin boosters with genuinely different mechanisms alongside three lifting devices, and selects among them according to what kind of ageing the face is actually showing. Our approach is restraint: choosing to do less is also a clinical decision.
| Medical director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Phone | +82-53-428-2700 |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Reference library | All booster and device references |
These columns provide general information and do not replace medical diagnosis or treatment. Results and side effects vary with skin condition, age and underlying health, and no outcome is guaranteed. Any decision to proceed should be made in an in-person consultation with a physician.
← Clinical reference library · Miso Clinic home
한국어 · English · 日本語 · 简体中文 · Español · Tiếng Việt · ภาษาไทย · Bahasa Indonesia